ProCE Banner Activity

MAGNITUDE: Update of Phase III Trial of First-line Niraparib With Abiraterone Acetate and Prednisone in mCRPC With HRR Gene Alterations

Capsule Summary
Conference Coverage
Slideset

Niraparib plus AAP significantly reduced risk of radiographic progression or death vs AAP as first-line therapy in patients with mCRPC and BRCA gene alterations.

Released: February 21, 2023

Expiration: February 20, 2024

No longer available for credit.
Begin Activity

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.